Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
NCT ID: NCT01281657
Last Updated: 2012-09-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
64 participants
OBSERVATIONAL
2011-02-28
2012-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Prescribed fingolimod 0.5 mg/day
fingolimod
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
fingolimod
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who have participated in a prior fingolimod clinical trials
Exclusion Criteria
* Any patient who has prematurely discontinued from the previous fingolimod trial
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
North Central Neurology Associates, PC
Cullman, Alabama, United States
The Research & Education Inst. of Alta Bates Summit Med. Grp
Berkeley, California, United States
Neuro-Therapeutics, Inc.
Pasadena, California, United States
University of California San Francisco
San Francisco, California, United States
Yale Multiple Sclerosis Center
New Haven, Connecticut, United States
Georgetown University/Lombardi Cancer Center
Washington D.C., District of Columbia, United States
Sunrise Clinical Research, Inc.
Hollywood, Florida, United States
University of Florida
Jacksonville, Florida, United States
University of Miami
Miami, Florida, United States
Neurological Associates
Pompano Beach, Florida, United States
Neurology Clinical Research, Inc.
Sunrise, Florida, United States
AMO Corporation
Tallahassee, Florida, United States
MS Center of Vero Beach
Vero Beach, Florida, United States
South Suburban Neurology
Flossmoor, Illinois, United States
Neurologic Associates, LTD
Palos Heights, Illinois, United States
Mercy Ruan Neurology Clinic Res Ct.
Des Moines, Iowa, United States
University of Kansas Medical Center
Kansas City, Kansas, United States
Mid America Neuroscience Institute
Lenexa, Kansas, United States
University of Maryland
Baltimore, Maryland, United States
Johns Hopkins MS Center
Baltimore, Maryland, United States
Caritas St. Elizabeth's Hospital
Boston, Massachusetts, United States
Springfield Neurology Associates, LLC
Springfield, Massachusetts, United States
Spectrum Health Medical Group, Neurology
Grand Rapids, Michigan, United States
Saint Luke's Hospital
Kansas City, Missouri, United States
The MS Center for Innovation in Care
St Louis, Missouri, United States
University of New Mexico Health Science Center
Albuquerque, New Mexico, United States
Mount Sinai School of Medicine
New York, New York, United States
Island Neurological Associates
Plainview, New York, United States
SUNY - Stony Brook University
Stony Brook, New York, United States
University of Toledo Health Science Campus
Toledo, Ohio, United States
MS Center of Oklahoma
Oklahoma City, Oklahoma, United States
Neurological Associates of Tulsa, Inc
Tulsa, Oklahoma, United States
University of Pennsylvania Health System
Philadelphia, Pennsylvania, United States
Thomas Jerfferson University Hospital
Philadelphia, Pennsylvania, United States
Vanderbilt University
Nashville, Tennessee, United States
University of Texas Medical School
Houston, Texas, United States
Integra Clinical Research
San Antonio, Texas, United States
University of Virginia Health System
Charlottesville, Virginia, United States
Swedish Neuroscience Institute
Seattle, Washington, United States
Dean Foundation
Madison, Wisconsin, United States
University of Wisconsin Madison
Madison, Wisconsin, United States
St. Luke's Medical Center
Milwaukee, Wisconsin, United States
Novartis Investigative Site
Burnaby, British Columbia, Canada
Novartis Investigative Site
Vancouver, British Columbia, Canada
Novartis Investigative Site
Victoria, British Columbia, Canada
Novartis Investigative Site
Halifax, Nova Scotia, Canada
Novartis Investigative Site
Kingston, Ontario, Canada
Novartis Investigative Site
London, Ontario, Canada
Novartis Investigative Site
Nepean, Ontario, Canada
Novartis Investigative Site
Ottawa, Ontario, Canada
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Greenfield Park, Quebec, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Québec, Quebec, Canada
Novartis Investigative Site
Sherbrooke, Quebec, Canada
Novartis Investigative Site
Regina, Saskatchewan, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CFTY720D2399E1
Identifier Type: -
Identifier Source: org_study_id